Implementing Sample Pooling and Aliquoting Techniques in Clinical Trials Under Regulatory Oversight

Introduction: Why Sample Pooling and Aliquoting Require Stringent Control

In large-scale clinical trials, efficient sample management is essential to minimize waste, improve throughput, and ensure timely analysis. Sample pooling and aliquoting are two widely used practices in bioanalytical laboratories for optimizing resources. However, both processes come with regulatory risks, particularly when poorly documented or improperly executed.

Regulatory authorities such as the FDA, EMA, and agencies under ICH guidance require detailed procedures and validations for pooling or aliquoting biological samples. This article provides a regulatory-compliant roadmap for implementing pooling and aliquoting techniques in clinical research, with focus on method validation, SOP development, risk mitigation, and CAPA planning.

What is Sample Pooling?

Sample pooling refers to combining biological specimens from multiple sources (e.g., different time points or subjects) into a single analytical run. It is often used for:

• Analyzing low-volume or rare samples
• Screening for analyte presence
• Quality control during method validation
• Retrospective PK assessments

Types of Pooling:

• Intrasubject pooling: Combining samples from the same subject
• Intersubject pooling: Combining samples across subjects (usually blinded)
• Matrix pool validation: Combining blank matrix samples for method development

What is Aliquoting?

Aliquoting is the process of dividing a larger biological sample into multiple smaller volumes (aliquots), each used for specific analytical procedures. This prevents repeated freeze-thaw cycles, reduces degradation risk, and facilitates storage logistics.

Common Practices for Aliquoting:

• Performing within 30 minutes of centrifugation
• Using pre-labeled, barcoded cryovials
• Documenting volume, time, analyst, and storage location in LIMS
• Ensuring aliquot traceability to original sample ID

Regulatory Considerations: FDA and EMA Expectations

While pooling and aliquoting are not explicitly banned, regulators mandate that such practices must:

• Be pre-specified in the study protocol or SAP (Statistical Analysis Plan)
• Be justified scientifically with documented rationale
• Maintain subject traceability and integrity of study blinding
• Be supported by validation data for pooled matrices
• Be governed by SOPs, with deviations recorded and investigated

In the 2021 FDA BIMO (Bioresearch Monitoring) inspection summary, several findings were issued for lack of validation for pooled matrices and undocumented aliquoting procedures.

Reference: ClinicalTrials.gov

Validation Requirements for Pooled Samples

When pooling is used for method validation or study analysis, the bioanalytical method must be assessed for:

• Recovery and matrix effect in the pooled sample
• Assay sensitivity post-dilution
• Analyte stability in mixed matrices
• Bias introduced due to heterogeneity

The pooled sample must meet the same acceptance criteria for accuracy and precision as individual samples. A sample validation report should accompany the pooled data.

Example Acceptance Criteria:

Case Study: Deviations in Pooling Documentation During Oncology Trial

A Phase II oncology trial utilized intersubject plasma pooling for pre-dose biomarker screening. During sponsor audit, it was found that:

• Pooling was performed by lab personnel but not pre-specified in the protocol
• No method validation was performed on pooled matrix
• Sample IDs were not traceable to individual subjects

CAPA Measures:

• Protocol amended to restrict pooling only during validation phase
• Validation study initiated for pooled plasma matrix
• SOPs revised to mandate traceability in all pooling events
• Retraining conducted for all sample processing personnel

Best Practices for Aliquoting SOPs

• Define time limits from sample receipt to aliquoting (e.g., ≤30 minutes)
• Include equipment requirements such as pre-chilled racks, automated pipettes
• Specify labeling requirements including date, time, analyst initials
• Ensure LIMS integration for real-time traceability
• Implement double-check by QA or second analyst for high-risk samples

Oversight and Inspection Readiness

During sponsor and regulatory audits, the following documentation must be available:

• Validated SOPs for pooling and aliquoting
• Raw data showing pre- and post-pooling concentrations
• Chain of custody logs for pooled samples
• Justification documents for protocol-level pooling decisions
• Corrective actions and retraining records if deviation occurred

Conclusion

Sample pooling and aliquoting can optimize lab efficiency but must be executed within a tightly regulated framework to ensure compliance and data integrity. By integrating pooling into protocol design, performing matrix-specific validation, ensuring traceability, and maintaining robust SOPs, sponsors and laboratories can prevent CAPAs, protect subjects, and withstand FDA/EMA inspections.